Coexistence of Anti-Phospholipid Antibodies and Endothelial Perturbation in Systemic Lupus Erythematosus Patients With Ongoing Prothrombotic State
- 18 March 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 95 (6) , 1425-1432
- https://doi.org/10.1161/01.cir.95.6.1425
Abstract
Background Anti-phospholipid antibodies (aPLs) were associated with an ongoing prothrombotic state in patients with systemic lupus erythematosus (SLE). Because aPLs are able to shift endothelial function toward procoagulant activity in vitro, we investigated the relationship among aPLs, ongoing prothrombotic state, and endothelial perturbation in SLE patients. Methods and Results We measured aPLs, anti-EC antibodies, circulating levels of prothrombin fragment F1+2 (F1+2), tumor necrosis factor-α (TNF-α), tissue-type plasminogen activator (TPA), and von Willebrand factor (vWF) in 43 SLE patients and 25 healthy subjects. Patients positive for aPLs (n=23) had a higher prevalence of anti-EC antibodies ( P =.02) and higher levels of F1+2 ( P =.003) than aPL(−) patients. Endothelial perturbation, defined by elevated plasma levels of both TPA and vWF, was significantly associated with aPL positivity ( P =.001). F1+2 >1 nmol/L (mean+2 SD of controls) was detected in all but one patient in whom aPL positivity and endothelial perturbation coexisted and in no aPL(+) patient without endothelial perturbation ( P =.0039). F1+2 was significantly correlated with vWF (ρ=.6, P =.004) and TPA (114 =.70, P =.0006) only in aPL(+) patients. Endothelial perturbation was closely associated with high values of TNF-α ( P =.0001), anti-phospholipid ( P =.001), and anti-EC antibodies ( P =.012). In 31 patients without a clinical history of thrombosis followed up for 3 years, aPL(+) patients with endothelial perturbation showed higher F1+2 and TNF-α values than aPL(+) patients without endothelial dysfunction. Conclusions This study shows that in SLE patients, aPL positivity is associated with an ongoing prothrombotic state only in the presence of endothelial perturbation. Our findings also suggest that aPLs and TNF-α might cooperate in inducing endothelial perturbation.Keywords
This publication has 26 references indexed in Scilit:
- Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies [see comments]Blood, 1994
- Lupus anticoagulant and increased thrombin generation in patients with systemic lupus erythematosus [letter; comment]Blood, 1994
- The antiphospholipid syndrome: ten years onThe Lancet, 1993
- The lupus anticoagulant and eicosanoidsProstaglandins, Leukotrienes & Essential Fatty Acids, 1993
- Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state [see comments]Blood, 1993
- Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? [see comments]Blood, 1993
- Detection of endothelial cell‐reactive immunoglobulin in patients with anti‐phospholipid antibodiesBritish Journal of Haematology, 1991
- In Vitro Studies of Antiphospholipid Antibodies and Its Cofactor, β2-Glycoprotein I, Show Negligible Effects on Endothelial Cell Mediated Protein C ActivationThrombosis and Haemostasis, 1991
- Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE DisordersAnnals of Internal Medicine, 1990
- Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.BMJ, 1990